Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology Sensus Healthcare, Inc., a developer of non-invasive and minimally invasive technologies for the treatment of both oncological and non-oncological skin conditions, has announced that it has initiated legal proceedings against…
Ono Pharma Files for Approval of Ripretinib (DCC-2618) to Treat Advanced Gastrointestinal Stromal Tumors in Japan Ono Pharmaceutical Co., Ltd. has announced the submission of a regulatory application in Japan seeking manufacturing and marketing approval for ripretinib (DCC-2618), an investigational…
Novo Nordisk Secures U.S. Approval for Awiqli, the First Once-Weekly Basal Insulin for Adults with Type 2 Diabetes Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and…
Invivoscribe Expands IVDR Portfolio with Certification of IdentiClone Dx IGH Assay Invivoscribe, a globally recognized leader in precision diagnostics and measurable residual disease (MRD) testing, has announced a major regulatory milestone with the successful certification of its IdentiClone Dx IGH…
Agenus to Host March 2026 Stakeholder Webcast Highlighting Progress of BOT + BAL Immunotherapy and Expanding Patient Access Across Multiple Tumor Types Agenus Inc., a biotechnology company focused on advancing innovative immuno-oncology therapies, has announced that it will host its…
Merck & Co., Inc. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML) Merck & Co.—known as MSD outside the United States and Canada—and Terns Pharmaceuticals, Inc. have announced a definitive agreement under which…
Kallisio Secures CE Mark for Stentra™ Precision Oral Immobilization System Kallisio has announced a significant regulatory milestone with the CE certification of its innovative Stentra intraoral positioning system under the European Union’s Medical Device Regulation, EU MDR 2017 This certification…
FDA Clears Corcept’s Lifyorli™ (relacorilant) in Combination with Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer Treatment Corcept Therapeutics Incorporated has announced a major regulatory milestone with the approval of its novel therapy, Lifyorli™ (relacorilant), by the U.S. Food and Drug Administration. This…
Incyte Reports New Appointments to Its Executive Leadership Team Incyte has announced a series of key leadership appointments within its executive team, signaling a strategic move to strengthen its organizational structure and support long-term growth across research, development, and commercial…
Poxel Announces Drawdown of Additional Tranche D PDR Bonds Under Continuation Plan POXEL SA, a biopharmaceutical firm specializing in innovative therapies for serious chronic diseases with metabolic origins, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, has announced a…
Element Science Earns Spot on Fast Company’s 2026 List of the World’s Most Innovative Companies Element Science has earned a place on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026, a recognition that highlights organizations driving…
U.S. Food and Drug Administration Approves Updated Label to Enable Faster Thawing of ADSTILADRIN® (nadofaragene firadenovec-vncg) Ferring Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an important label update for ADSTILADRIN, introducing a faster and more…